Tradestie Institutional Equity Comparison Engine

SGMO vs CLYM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while SGMO counters with relative strength in Valuation, Options & Structure. Fundamentally, SGMO trades at 0.4x Forward P/E with -175.5% operating margin (+88.4% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner SGMO
SGMO 0.4x vs CLYM N/M Fwd P/E
Growth & Margin Winner CLYM
Op Margin -175.5% vs 0.0% ยท YoY +88.4% vs +0.0%
Momentum & Technical Winner CLYM
1Y -76.0% vs +434.5% ยท 52W Pos 9% vs 50%
Options & Structure Winner SGMO
UNCLASSIFIED (71st %ile IV) vs UNCLASSIFIED (N/A IV)
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
1M Return -40.82%
1Y Return -76.04%
Forward P/E 0.4x
Unified AI Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.99
-3.52% 1D
Market Cap $638.5M
1M Return +1.78%
1Y Return +434.49%
Forward P/E N/M
Unified AI Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SGMO -76.04% CLYM +434.49% Spread: +478.64 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SGMO TTM Op. Margin: -175.5% CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGMO vs CLYM. Trailing 12-month operating profitability (SGMO -175.5% vs CLYM 0.0%) and valuation multiples (SGMO 0.4x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SGMO (4) vs CLYM (5)
Institutional Metric SGMO CLYM Criterion Row Winner
Market Capitalization Scale $55.9M $638.5M Larger Scale CLYM
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Forward P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Revenue Growth (YoY) Growth +88.4% +0.0% Higher Growth SGMO
Operating Margin (TTM) Profitability -175.5% 0.0% Higher Margin CLYM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2891.8% -29.3% Higher ROE CLYM
52-Week Range Position Momentum 9% ($0โ€“$1) 50% ($2โ€“$18) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.49ฮฒ ยท 206% Vol 1.51ฮฒ ยท 114% Vol Lower Realized Risk CLYM
Unified Institutional Score Composite Signal 52.0 / 100 (HOLD) 41.9 / 100 (SELL) Higher Composite SGMO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SGMO vs CLYM Buy Guide
SGMO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live SGMO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SGMO nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.